0.5235
price up icon2.02%   0.00976
 
loading
Precedente Chiudi:
$0.5137
Aprire:
$0.52
Volume 24 ore:
95,109
Relative Volume:
0.39
Capitalizzazione di mercato:
$31.81M
Reddito:
-
Utile/perdita netta:
$-68.80M
Rapporto P/E:
-0.2553
EPS:
-2.05
Flusso di cassa netto:
$-59.06M
1 W Prestazione:
-11.20%
1M Prestazione:
-10.94%
6M Prestazione:
-59.05%
1 anno Prestazione:
-15.47%
Intervallo 1D:
Value
$0.508
$0.547
Intervallo di 1 settimana:
Value
$0.451
$0.61
Portata 52W:
Value
$0.451
$1.79

Passage Bio Inc Stock (PASG) Company Profile

Name
Nome
Passage Bio Inc
Name
Telefono
(267) 866-0312
Name
Indirizzo
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Name
Dipendente
85
Name
Cinguettio
@passage_bio
Name
Prossima data di guadagno
2024-11-11
Name
Ultimi documenti SEC
Name
PASG's Discussions on Twitter

Confronta PASG con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
PASG 0.5369 31.81M 0 -68.80M -59.06M -2.05
VRTX 448.93 115.43B 10.63B -479.80M -1.35B 13.33
REGN 746.47 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 597.75 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 246.28 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 108.14 24.89B 3.30B -501.07M 1.03B 11.54

Passage Bio Inc Stock (PASG) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-09-03 Iniziato Rodman & Renshaw Buy
2022-03-08 Downgrade JP Morgan Overweight → Neutral
2022-01-19 Downgrade Goldman Buy → Neutral
2021-07-01 Iniziato Raymond James Outperform
2021-06-15 Iniziato BTIG Research Buy
2021-03-04 Aggiornamento Goldman Neutral → Buy
2021-02-04 Iniziato Guggenheim Buy
2021-01-25 Iniziato Wedbush Outperform
2021-01-04 Aggiornamento JP Morgan Neutral → Overweight
2020-12-11 Iniziato Citigroup Neutral
2020-08-14 Downgrade JP Morgan Overweight → Neutral
2020-06-25 Downgrade Goldman Buy → Neutral
2020-03-25 Iniziato Chardan Capital Markets Buy
2020-03-24 Iniziato Cowen Outperform
2020-03-24 Iniziato Goldman Buy
2020-03-24 Iniziato JP Morgan Overweight
Mostra tutto

Passage Bio Inc Borsa (PASG) Ultime notizie

pulisher
Nov 20, 2024

Passage Bio CEO Will Chou to Share Insights at Guggenheim Healthcare Innovation Conference! - MSN

Nov 20, 2024
pulisher
Nov 18, 2024

Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateOn November 13, 2024, Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company focusing on innovative therapies for rare cardiopulmonary dise - Defense World

Nov 18, 2024
pulisher
Nov 18, 2024

Horizon Space Acquisition I Corp. Approved for Listing on Nasdaq Capital Market - Defense World

Nov 18, 2024
pulisher
Nov 18, 2024

Seres Therapeutics Receives Notification from Nasdaq Regarding Bid Price Requirement - Defense World

Nov 18, 2024
pulisher
Nov 18, 2024

BioRestorative Therapies Provides Business Update and Financial Results for Q3 2024 - Defense World

Nov 18, 2024
pulisher
Nov 18, 2024

Nikola Corporation Enters Material Definitive Agreements, Modifies Convertible Notes – 8-K Filing Highlights - Defense World

Nov 18, 2024
pulisher
Nov 18, 2024

Cognition Therapeutics Reports Financial Results for the Third Quarter 2024UNAUDITED – On November 13, 2024, Cognition Therapeutics, Inc. (NASDAQ: CGTX) disclosed its financial results for the third quarter ending September 30, 2024. Within the detai - Defense World

Nov 18, 2024
pulisher
Nov 18, 2024

MRC Global Inc. Enters into Fifth Amended and Restated Loan Agreement - Defense World

Nov 18, 2024
pulisher
Nov 18, 2024

Air Industries Group to Release Financial Results for Q3 2024 - Defense World

Nov 18, 2024
pulisher
Nov 18, 2024

Intevac (NASDAQ: IVAC) Enters into Letter Agreement with Palogic Value Management, L.P.Santa Clara, CA, November 13, 2024 – Intevac, Inc. (NASDAQ: IVAC) disclosed today in a Form 8-K filing that on November 8, 2024, the company entered into a letter - Defense World

Nov 18, 2024
pulisher
Nov 18, 2024

Sound Point Meridian Capital, Inc. (NYSE: SPMC) Announces Financial Results for Quarter Ended September 30, 2024 - Defense World

Nov 18, 2024
pulisher
Nov 18, 2024

Tetra Tech Reports Record Fiscal 2024 and Fourth Quarter ResultsOn November 13, 2024, Tetra Tech, Inc. (NASDAQ: TTEK) released its financial results for the fourth fiscal quarter and the fiscal year ended September 29, 2024. According to the report - Defense World

Nov 18, 2024
pulisher
Nov 18, 2024

Roth CH Acquisition II Files 8-K Report with SEC Detailing Company Updates and Investor Presentation - Defense World

Nov 18, 2024
pulisher
Nov 18, 2024

Capricor Therapeutics Announces Financial Results for Third Quarter 2024 and Strategic DevelopmentsSAN DIEGO, November 13, 2024 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR) recently disclosed its financial outcomes for the third - Defense World

Nov 18, 2024
pulisher
Nov 18, 2024

Predictive Oncology Inc. Issues Press Release Detailing Financial Results for Q3 2024Predictive Oncology Inc., a leading biopharmaceutical company, released a pivotal press release detailing its financial results for the quarter ending September 30 - Defense World

Nov 18, 2024
pulisher
Nov 18, 2024

374Water Inc. Reports Third Quarter 2024 Results and Business Update - Defense World

Nov 18, 2024
pulisher
Nov 18, 2024

Broadwind, Inc. Reports Financial Results for Quarter Ending September 30, 2024 - Defense World

Nov 18, 2024
pulisher
Nov 18, 2024

Workhorse Group Reschedules Earnings Call to November 19, 2024 - Defense World

Nov 18, 2024
pulisher
Nov 16, 2024

Cabaletta Bio Reports Q3 2024 Financial Results and Clinical Trial Advancements - MyChesCo

Nov 16, 2024
pulisher
Nov 15, 2024

Passage Bio stock hits 52-week low at $0.54 amid market challenges - Investing.com India

Nov 15, 2024
pulisher
Nov 15, 2024

Layoff Tracker: Sensei to Cut 46% of Workforce, Close Research Site - BioSpace

Nov 15, 2024
pulisher
Nov 15, 2024

Passage Bio Advances PBFT02 Gene Therapy Program Amidst Positive Q3 2024 Results - MSN

Nov 15, 2024
pulisher
Nov 14, 2024

Vestal Point Capital, LP Increases Stake in Passage Bio Inc - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Passage Bio Achieves Milestones in Gene Therapy Trials - Yahoo Finance

Nov 14, 2024
pulisher
Nov 13, 2024

Passage Bio Shows Progress in Gene Therapy Trials - TipRanks

Nov 13, 2024
pulisher
Nov 13, 2024

PASGPassage Bio, Inc. Latest Stock News & Market Updates - StockTitan

Nov 13, 2024
pulisher
Nov 13, 2024

Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights - GlobeNewswire

Nov 13, 2024
pulisher
Nov 13, 2024

Passage Bio's Q3 Shows Progress: Clinical Trial Advances, Cash Runway Extended to 2026 | PASG Stock News - StockTitan

Nov 13, 2024
pulisher
Nov 13, 2024

Annovis Bio Advances Alzheimer’s Treatment with Phase 3 Trials and Financial Updates - MyChesCo

Nov 13, 2024
pulisher
Nov 08, 2024

Cabaletta Bio to Spotlight Groundbreaking Cell Therapies at Guggenheim's Healthcare Innovation Conference! - MyChesCo

Nov 08, 2024
pulisher
Nov 06, 2024

Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference - StockTitan

Nov 06, 2024
pulisher
Oct 31, 2024

R. Nolan Townsend, Sandi See Tai, MD, and Kim G. Johnson, MD, on Gene Therapy for APOE4 Homozygous Alzheimer Disease - CGTLive™

Oct 31, 2024
pulisher
Oct 31, 2024

Data Roundup: October 2024 Features Update for TCR-Based Autologous Cell Therapy in Melanoma, the First Clinical Demonstration of Therapeutic RNA Editing in Humans, and More - CGTLive™

Oct 31, 2024
pulisher
Oct 24, 2024

Passage Bio reports advances in gene therapy for dementia - Investing.com

Oct 24, 2024
pulisher
Oct 24, 2024

Gene therapy shows promise in frontotemporal dementia study - Investing.com

Oct 24, 2024
pulisher
Oct 24, 2024

Gene therapy shows promise in frontotemporal dementia study By Investing.com - Investing.com South Africa

Oct 24, 2024
pulisher
Oct 24, 2024

Passage Bio reports advances in gene therapy for dementia By Investing.com - Investing.com South Africa

Oct 24, 2024
pulisher
Oct 24, 2024

Passage Bio Presents Preclinical and Interim Clinical Data - GlobeNewswire

Oct 24, 2024
pulisher
Oct 21, 2024

Goldman Sachs, Morgan Stanley bullish on BioAge, cite Lilly relationship - MSN

Oct 21, 2024
pulisher
Oct 20, 2024

Will Passage Bio See An Uplift? Frontotemporal Dementia Trial Data Holds The Key - RTTNews

Oct 20, 2024
pulisher
Oct 17, 2024

PASG stock touches 52-week low at $0.55 amid market challenges - Investing.com

Oct 17, 2024
pulisher
Oct 13, 2024

Plexxikon, Inc. - Scrip

Oct 13, 2024
pulisher
Oct 11, 2024

Passage Bio Inc [PASG] 10% Owner makes an insider purchase of 39,300 shares worth 27903.0. - Knox Daily

Oct 11, 2024
pulisher
Oct 11, 2024

Director Mayson Howard John sale 4,000 shares of Ovintiv Inc [OVV] - Knox Daily

Oct 11, 2024
pulisher
Oct 11, 2024

Passage Bio Inc (PASG) Stock: A Year of Highs and Lows - The InvestChronicle

Oct 11, 2024
pulisher
Oct 10, 2024

Passage Bio Welcomes Tom Kassberg to Board, Aiming to Strengthen Strategic Vision - MSN

Oct 10, 2024
pulisher
Oct 08, 2024

Passage Bio stock hits 52-week low at $0.57 amid market challenges - Investing.com Australia

Oct 08, 2024
pulisher
Oct 08, 2024

Jim Wilson’s new gene therapy company Gemma is getting up to $100M from Brazil - Head Topics

Oct 08, 2024
pulisher
Oct 07, 2024

Passage Bio stock hits 52-week low at $0.57 amid market challenges By Investing.com - Investing.com South Africa

Oct 07, 2024
pulisher
Oct 07, 2024

Frontotemporal Dementia Pipeline 2024: Clinical Trials - openPR

Oct 07, 2024

Passage Bio Inc Azioni (PASG) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Capitalizzazione:     |  Volume (24 ore):